Immunovant IMVT
NASDAQ IMVT
$33.65 -0.13 (-0.38%)
As of: Oct 1, 2026 · 3:59 PM EDT

Immunovant (IMVT) Return on Equity [ROE] (2019 - 2026)

Updated

Immunovant's Return on Equity [ROE] was -67.79% in fiscal Q1 2027 (quarter ended Jun 30, 2026), up 0.19 percentage points from -67.98% a year earlier but down 12.79 percentage points from the prior quarter.

Analysis

Immunovant (IMVT) Return on Equity [ROE] (2019 - 2026) Analysis & Trends

For FY2026 (ended Mar 31, 2026), Return on Equity [ROE] at Immunovant came in at -64.82%, down 2.36 percentage points from FY2025.

  • Return on Equity [ROE] has now declined for four consecutive fiscal years, with a five-year change of -20.57 percentage points (FY2021 to FY2026).
  • In earlier fiscal years, Return on Equity [ROE] was -62.46% in FY2025 (-9.54 pp), -52.91% in FY2024 (-2.22 pp), -50.69% in FY2023 (-14.30 pp) and -36.39% in FY2022 (+7.86 pp).
  • Quarterly Return on Equity [ROE] has moved between -95.48% (fiscal Q3 2025) and -26.44% (fiscal Q3 2022) over five years.
  • Compared with a year earlier, Return on Equity [ROE] has increased for three straight quarters, with an average year-over-year change of -4.39 percentage points over the last eight quarters.
  • The best year-over-year quarter for Return on Equity [ROE] over five years was fiscal Q3 2026 (a gain of 33.82 percentage points); the worst was fiscal Q2 2024 (a drop of 50.04 percentage points).
  • Per Business Quant data, IMVT's Return on Equity [ROE] in the three fiscal quarters before Q1 2027 was -55.00% (Q4 2026), -61.65% (Q3 2026) and -82.37% (Q2 2026).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 25.32%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 7.21%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 84.40%
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 21.39%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 83.75%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -18.38%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 4.97%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 22.24%
10 Immunovant 6.97 Bn 6.97 Bn - -67.79%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -67.79%
Mar 31, 2026 -55.00%
Dec 31, 2025 -61.65%
Sep 30, 2025 -82.37%
Jun 30, 2025 -67.98%
Mar 31, 2025 -78.08%
Dec 31, 2024 -95.48%
Sep 30, 2024 -65.01%
Jun 30, 2024 -46.89%
Mar 31, 2024 -39.99%
Dec 31, 2023 -52.29%
Sep 30, 2023 -92.54%
Jun 30, 2023 -73.83%
Mar 31, 2023 -54.29%
Dec 31, 2022 -49.04%
Sep 30, 2022 -42.50%
Jun 30, 2022 -36.77%
Mar 31, 2022 -32.15%
Dec 31, 2021 -26.44%
Sep 30, 2021 -28.41%
API Access

Immunovant Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=IMVT&period=max&api_key=YOUR_API_KEY